RULES FOR AN EMERGENT MARKET: Selling paintings in late seventeenth-century London

Conditions of sale were a feature of the Roman auction, and probably published along with the written public announcement, the proscriptio , that preceded a sale. When such conditions appeared on the front pages of printed sale catalogues for paintings, prints and drawings in late seventeenth-century London, then, this was nothing new; but the rules themselves were almost certainly modified to fit the circumstances then prevailing. Here I wish to examine those rules and explore the rationale for either modifying traditional elements among them or introducing some for - it seems - the first time. I will also use the exploration as an occasion to conduct two additional probes. One of these will be into the likely level and structure of prices in these early London sales, the inquiry into structure revealing that many sales were two-in-one, appealing to dual audiences. The other probe will show that the market was also segmented by quality and location, which must have restricted the possibilities for immediate profitable resale and thus the likelihood that individuals' bids were influenced by those of others.

Rules versus play in early modern art market

The paper identifies and tries to account for the forms taken in selected art markets for the selling of paintings, as a response to specific features and constraints in the local regulatory environment. Our analytical historics cover 15"' century Bruges, 16th century Antwerp, 17"' century Amsterdam, and early 18"' century London and Paris. They yield some evidence that : (1) restrictive guilds did not succeed in stifling innovation, though innovators were forcecl to take indirect routes and to adopt forms not always the most efficient; (2) where circumstances allowed a choice of auction form (English or Dutch) the method selected matched the prior expérience of buyers (low or high respectively) ; and (3) in the single instance where guilds were open to cooperation across skill catégories this coincided with a series of marketing experiments and a range of novel products.Regulation, Institutions, Markets

Imaging Lunar Craters with the Lucy Long Range Reconnaissance Imager (L'LORRI): A Resolution Test for NASA's Lucy Mission

NASA's Lucy mission is designed to better understand the unique population of Trojan asteroids. Trojans were probably captured in Jupiter's L4 and L5 points early in the solar system's evolution and little altered since then. A critical investigation of Lucy is to use its highest-resolution camera, the Lucy Long Range Reconnaissance Imager (L'LORRI), to image Trojans' surfaces to understand their geology and impact crater populations. Through crater statistics, the population of smaller bodies that produced those impacts, relative age differences across the bodies, and other comparative investigations between bodies can be studied. Mapping the crater population to the minimum diameters needed to achieve Lucy's objectives might require image subsampling and deconvolution ("processing") to improve the spatial resolution, a process whereby multiple, slightly offset images are merged to create a single, better-sampled image and deconvolved with L'LORRI's point-spread function. Lucy's first Earth Gravity Assist (EGA1) provided an opportunity to test this process's accuracy using L'LORRI images of the Moon, whose crater population is well characterized and therefore provides ground-truth testing. Specifically, the lunar crater imaging by L'LORRI during EGA1 allowed us to compare crater statistics derived from raw and processed L'LORRI images with ground-truth statistics derived from higher-resolution lunar imaging from other missions. The results indicate the processing can improve impact crater statistics such that features can be identified and measured to ~70% the diameter that they can otherwise be reliably mapped on native L'LORRI images. This test's results will be used in the observation designs for the Lucy flyby targets

Preliminary Interdependency Analysis: An Approach to Support Critical Infrastructure Risk Assessment

We present a methodology, Preliminary Interdependency Analysis (PIA), for analysing interdependencies between critical infrastructure (CI). Consisting of two phases – qualitative analysis followed by quantitative analysis – an application of PIA progresses from a relatively quick elicitation of CI-interdependencies to the building of representative CI models, and the subsequent estimation of any resilience, risk or criticality measures an assessor might be interested in. By design, stages in the methodology are both flexible and iterative, resulting in interacting CI models that are scalable and may vary significantly in complexity and fidelity, depending on the needs and requirements of an assessor. For model parameterisation, one relies on a combination of field data, sensitivity analysis and expert judgement. Facilitated by dedicated software tool support, we illustrate PIA by applying it to a complex case-study of interacting Power (distribution and transmission) and Telecommunications networks in the Rome area. A number of studies are carried out, including: 1) an investigation of how “strength of dependence” between the CIs’ components affects various measures of risk and uncertainty, 2) for resource allocation, an exploration of different, but related, notions of CI component importance, and 3) highlighting the impact of model fidelity on the estimated risk of cascades

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

To identify novel genes associated with ALS, we undertook two lines of investigation. We carried out a genome-wide association study comparing 20,806 ALS cases and 59,804 controls. Independently, we performed a rare variant burden analysis comparing 1,138 index familial ALS cases and 19,494 controls. Through both approaches, we identified kinesin family member 5A (KIF5A) as a novel gene associated with ALS. Interestingly, mutations predominantly in the N-terminal motor domain of KIF5A are causative for two neurodegenerative diseases: hereditary spastic paraplegia (SPG10) and Charcot-Marie-Tooth type 2 (CMT2). In contrast, ALS-associated mutations are primarily located at the C-terminal cargo-binding tail domain and patients harboring loss-of-function mutations displayed an extended survival relative to typical ALS cases. Taken together, these results broaden the phenotype spectrum resulting from mutations in KIF5A and strengthen the role of cytoskeletal defects in the pathogenesis of ALS.Peer reviewe

The development and validation of a scoring tool to predict the operative duration of elective laparoscopic cholecystectomy

Background: The ability to accurately predict operative duration has the potential to optimise theatre efficiency and utilisation, thus reducing costs and increasing staff and patient satisfaction. With laparoscopic cholecystectomy being one of the most commonly performed procedures worldwide, a tool to predict operative duration could be extremely beneficial to healthcare organisations. Methods: Data collected from the CholeS study on patients undergoing cholecystectomy in UK and Irish hospitals between 04/2014 and 05/2014 were used to study operative duration. A multivariable binary logistic regression model was produced in order to identify significant independent predictors of long (> 90 min) operations. The resulting model was converted to a risk score, which was subsequently validated on second cohort of patients using ROC curves. Results: After exclusions, data were available for 7227 patients in the derivation (CholeS) cohort. The median operative duration was 60 min (interquartile range 45–85), with 17.7% of operations lasting longer than 90 min. Ten factors were found to be significant independent predictors of operative durations > 90 min, including ASA, age, previous surgical admissions, BMI, gallbladder wall thickness and CBD diameter. A risk score was then produced from these factors, and applied to a cohort of 2405 patients from a tertiary centre for external validation. This returned an area under the ROC curve of 0.708 (SE = 0.013, p  90 min increasing more than eightfold from 5.1 to 41.8% in the extremes of the score. Conclusion: The scoring tool produced in this study was found to be significantly predictive of long operative durations on validation in an external cohort. As such, the tool may have the potential to enable organisations to better organise theatre lists and deliver greater efficiencies in care

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

The James Webb Space Telescope Mission

Twenty-six years ago a small committee report, building on earlier studies, expounded a compelling and poetic vision for the future of astronomy, calling for an infrared-optimized space telescope with an aperture of at least $4m$. With the support of their governments in the US, Europe, and Canada, 20,000 people realized that vision as the $6.5m$ James Webb Space Telescope. A generation of astronomers will celebrate their accomplishments for the life of the mission, potentially as long as 20 years, and beyond. This report and the scientific discoveries that follow are extended thank-you notes to the 20,000 team members. The telescope is working perfectly, with much better image quality than expected. In this and accompanying papers, we give a brief history, describe the observatory, outline its objectives and current observing program, and discuss the inventions and people who made it possible. We cite detailed reports on the design and the measured performance on orbit.Comment: Accepted by PASP for the special issue on The James Webb Space Telescope Overview, 29 pages, 4 figure

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research